logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

CF PHARMTECH spent HK$830,000 to repurchase 24,000 shares on December 30th.

date
20:53 30/12/2025
avatar
GMT Eight
Changfeng Pharmaceutical (02652) announced that on December 30, 2025, it spent HKD 830,200 to repurchase 24,000 shares.
CF PHARMTECH (02652) announced on December 30, 2025 that it will spend HK$830,200 to repurchase 24,000 shares.
Related Articles
HK Stock
Air China Limited (00753) plans to purchase 60 Airbus A320NEO series aircraft from Airbus.
HK Stock
DL Holdings GP (01709): CSRC approves upgrading the first-category license.
HK Stock
CHINA SAFTOWER (08623) changes hands: The original major shareholder transferred 25% of the shares, and executive director Luo Qicong becomes the new major shareholder.
Air China Limited (00753) plans to purchase 60 Airbus A320NEO series aircraft from Airbus.
HK Stock
DL Holdings GP (01709): CSRC approves upgrading the first-category license.
HK Stock
CHINA SAFTOWER (08623) changes hands: The original major shareholder transferred 25% of the shares, and executive director Luo Qicong becomes the new major shareholder.
HK Stock
RECOMMEND
Crossing 2025, Can The Year‑End Rally Extend To The Close? Review Of This Week’s Ten Brokerage Strategies
Crossing 2025, Can The Year‑End Rally Extend To The Close? Review Of This Week’s Ten Brokerage Strategies
icon
29/12/2025
IPO Fundraising Tops The World, A Review Of Ten Key Themes For Hong Kong Stocks In 2025
IPO Fundraising Tops The World, A Review Of Ten Key Themes For Hong Kong Stocks In 2025
icon
29/12/2025
Will The U.S. Market Maintain Its Global Leadership Beyond 2025?
Will The U.S. Market Maintain Its Global Leadership Beyond 2025?
icon
29/12/2025
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.